---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046792"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:30:15.646383+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical Q3 2024 net income $1.7M, raises guidance; largest customer revenue expected to decline $31-38M in 2025

## Summary
- Net product sales $28.3M (+31% YoY); gross profit $6.2M (+183%); gross margin 22% vs 9%.
- Net income $1.7M vs loss $1.9M in Q3 2023; adjusted EBITDA $2.8M vs negative $1.2M.
- Cash from operations $4.3M; cash and equivalents $18.3M, up from $11.9M at June 30.
- 2024 guidance raised: net sales $98-101M, gross profit $15-17M, adjusted EBITDA $4-5M.
- Largest customer extended through Dec 2025 but expects volume decline of $31-38M in 2025; company aims to offset with new contracts.

## SEC filing metadata
- accession: 0001628280-24-046792
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000162828024046792/0001628280-24-046792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000162828024046792/rmti-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046792
- JSON: https://secwatch.observer/filing/0001628280-24-046792.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046792.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.